113. Muscular dystrophy
567 clinical trials,   442 drugs   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-007236-18-IT
(EUCTR)
01/12/200811/12/2008Effects of cardioprotective therapy, carvedilol vs ramipril, in patients affected by Duchenne and Becker muscular dystrophy. Clinical significance and prognostic value of Cardiac Magnetic Resonance study. - NDEffects of cardioprotective therapy, carvedilol vs ramipril, in patients affected by Duchenne and Becker muscular dystrophy. Clinical significance and prognostic value of Cardiac Magnetic Resonance study. - ND Duchenne and Becher muscular dystrophy
MedDRA version: 9.1;Level: LLT;Classification code 10013801;Term: Duchenne muscular dystrophy
Trade Name: DILATREND
INN or Proposed INN: Carvedilol
Trade Name: TRIATEC
INN or Proposed INN: Ramipril
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLINULLNot RecruitingFemale: no
Male: yes
Italy
2NCT00819845
(ClinicalTrials.gov)
December 20088/1/2009Ramipril Versus Carvedilol in Duchenne and Becker PatientsEffects of Cardioprotective Therapy, Carvedilol vs Ramipril, in Patients Affected by Duchenne and Becker Muscular Dystrophy. Clinical Significance and Prognostic Value of Cardiac Magnetic Resonance Study.Duchenne Muscular Dystrophy;Becker Muscular DystrophyDrug: carvedilol;Drug: ramiprilCatholic University, ItalyNULLRecruiting2 Years45 YearsMale194Phase 4Italy
3NCT00606775
(ClinicalTrials.gov)
December 200722/1/2008The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular DystrophyCarvedilol for the Prevention of Minor Cardiac Damage and Cardiac Function in Duchenne Muscular DystrophyDuchenne Muscular Dystrophy;CardiomyopathiesDrug: CarvedilolSuzuka HospitalNagoya UniversityRecruiting8 Years45 YearsMale60Phase 4Japan
4EUCTR2006-003075-12-IE
(EUCTR)
13/07/2006Effect of carvedilol on left ventricular systolic and diastolic function and the neurohormonal axis in patients with Duchenne muscular dystrophy and left ventricular dysfunction.Effect of carvedilol on left ventricular systolic and diastolic function and the neurohormonal axis in patients with Duchenne muscular dystrophy and left ventricular dysfunction. Duchenne muscular dystrophy is an X-linked inherited disorder which primarily affects skeletal muscle through a mutation in dystrophin which maps to the long arm of the X chromosome (Xp21). Patients with skeletal myopathy such as DMD eventually progress to develop dilated cardiomyopathy as dystrophin is expressed in all forms of muscle including cardiac and smooth muscle. Often the cause of death in patients with DMD is cardiac failure and arrhythmia.Trade Name: Eucardic
Product Name: Eucardic
Product Code: No code
INN or Proposed INN: CARVEDILOL
Department Of Paediatric CardiologyNULLNAFemale: yes
Male: yes
30Phase 4Ireland